Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates
the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA …
the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA …
Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases
D van De Berg, Z Kis, CF Behmer, K Samnuan… - npj Vaccines, 2021 - nature.com
Rapid-response vaccine production platform technologies, including RNA vaccines, are being
developed to combat viral epidemics and pandemics. A key enabler of rapid response is …
developed to combat viral epidemics and pandemics. A key enabler of rapid response is …
Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer
Self-amplifying RNA (saRNA) vaccines are highly advantageous, as they result in enhanced
protein expression compared to mRNA (mRNA), thus minimizing the required dose. …
protein expression compared to mRNA (mRNA), thus minimizing the required dose. …
[HTML][HTML] Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines
Self-amplifying RNA (saRNA) is a next-generation vaccine platform, but like all nucleic acids,
requires a delivery vehicle to promote cellular uptake and protect the saRNA from …
requires a delivery vehicle to promote cellular uptake and protect the saRNA from …
Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA
Self-amplifying RNA (saRNA) is a cutting-edge platform for both nucleic acid vaccines and
therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which …
therapeutics. saRNA is self-adjuvanting, as it activates types I and III interferon (IFN), which …
Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA
K Samnuan, AK Blakney, PF McKay, RJ Shattock - BioRxiv, 2021 - biorxiv.org
Self-amplifying RNA (saRNA) vaccines are able to induce a higher antigen-specific immune
response with a more cost-effective and rapid production process compared to plasmid …
response with a more cost-effective and rapid production process compared to plasmid …
Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity
A vaccine antigen, when launched as DNA or RNA, can be presented in various forms,
including intracellular, secreted, membrane‐bound, or on extracellular vesicles (EVs). Whether …
including intracellular, secreted, membrane‐bound, or on extracellular vesicles (EVs). Whether …
Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
…, M Ulaszewska, CD Bissett, K Hu, K Samnuan… - Nature …, 2021 - nature.com
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet
there is limited data on the immune response induced by heterologous vaccination regimens …
there is limited data on the immune response induced by heterologous vaccination regimens …
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
…, M Ricamara, P Rogers, H Sallah, K Samnuan… - …, 2022 - thelancet.com
Background Lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is a novel
technology formulated as a low dose vaccine against COVID-19. Methods A phase I first-in-…
technology formulated as a low dose vaccine against COVID-19. Methods A phase I first-in-…
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients
The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates
the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA …
the development of a rapidly scalable vaccine. Here, we present a self-amplifying RNA …
